Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price99.68 USD
Fair value109.12
RatingAVOID
Our investment reviews on this name
2026-09-21Read Markdown111.36-10.5% to today ✓
2026-07-02Read Markup88.52+12.6% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Agilysys, Inc. holds its Markdown at $99.68. Consolidating, no directional conviction, held for 36 days.
As held on the ledger · 2026-09-24
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 36 days
Price at the screen
$99.68
Valuation
65.58 trailing · 31.14 forward price to earnings
Values screen
PASS
Beta
0.38
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.07%
Below 33%
Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.30%
Below 33%
Cash held in interest-bearing accounts and securities is 4.3% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Agilysys, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 10% discount to our $109.12 fair value, moderate competitive moat, 14.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-24 screen. The gold marker is the market price at the same screen. A 9.5% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-24 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Agilysys Trades Above Fair Value With Little Room
Every time a hotel upgrades its booking system or a resort streamlines its kitchen orders the software must keep pace with real operations. Agilysys supplies those tools yet we pass. The shares sit just above our fair value estimate and carry a forward multiple of 33.5 times for revenue growth of only 12 percent.
Profit margins stand at 12 percent and return on equity reaches 13 percent with a moderate moat. Those figures are respectable and the ethical screen clears without issue. Still the valuation offers no meaningful buffer against slower hospitality spending.
High multiples on steady but unspectacular returns often leave investors exposed when growth moderates. The six analyst targets sit well above current levels yet the modest margin of safety tells its own story. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AGYS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$99.68-10.5%Entry 8
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131. Since the last review it entered the Tech 100; its composite score rose.
2026-09-21Markdown · changed$111.36-4.6%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131.
2026-08-21Markup$116.71+9.4%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131.
2026-07-20Markup$106.68+20.5%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131.
2026-07-18Markup$88.52+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131.
2026-07-16Markup$88.52+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $131.
2026-07-03Markup$88.52+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$88.52Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
